Anzeige
Mehr »
Montag, 29.12.2025 - Börsentäglich über 12.000 News
Doppelter Hebel: 2026 - das Jahr für diesen Med-Tech SmallCap!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
26 Leser
Artikel bewerten:
(0)

Biochip Market Size Projected to Reach $25.8 Billion by 2024: Grand View Research, Inc.

SAN FRANCISCO, August 24, 2016 /PRNewswire/ --

Globalbiochips anticipated marketto reach USD 25.84 billion by 2024, according to a new report by Grand View Research, Inc. Growing adoption of personalized medicine and rapid technological advancements in the biochips market along with high market demand from proteomic and genomic applications is expected to drive market growth.

(Logo: http://photos.prnewswire.com/prnh/20150105/723757 )

Anticipated launch and commercialization of novel products for diagnosis and treatment including laboratory- and non-laboratory-based research are expected to further reinforce growth in demand. Improvements in accuracy, resolution, and preparation procedures for the technology coupled with reduction in costs of associated materials are expected to fuel growth over the forecast period.

Ongoing developments related to further miniaturization of biochips are expected to enhance their applicability and additional usage for genetic sequencing methodologies, such as cancer genomics. Their usage is also expected to aid reduction in the cost of genome profiling, which is a factor likely to drive demand for the next step of genetic analysis, i.e., protein expression analysis. Consequently, a growth in the number of such protein profiling studies is expected to directly fuel demand for genomic and proteomic labeling techniques through to 2024.

Browse full research report with TOC on "Biochip Market Analysis by Type, (DNA Chips, Lab-On-a-Chip, Protein Chips, Cancer Diagnosis and Treatment, Gene Expression, Single Nucleotide Polymorphism (SNP) Genotyping, Genomics, Drug Discovery, Agricultural Biotechnology, Proteomics, Expression Profiling, High Throughput Screening), by End Use (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research Institutes), and Segment Forecasts to 2024" at: http://www.grandviewresearch.com/industry-analysis/biochips-market

Further Key Findings From the Report Suggest:

  • DNA chips form the largest revenue-generating segment of the biochip applications. Major contribution to this share comes from usage in cancer diagnostics/treatment and drug discovery applications. DNA chips accounted for around a third of the global market revenue in 2015. The other notable contributing segments to application of biochips include gene expression, single nucleotide polymorphism genotyping, genomic studies, and agricultural biotechnology.
  • The market is expected to have a high potential for growth as the technology has numerous applications to aid the miniaturization of molecular biology and biochemical & chemical assays. Over time, such miniaturization is expected to benefit medical technologies in terms of cost and input requirements.
  • DNA chips, lab-on-a-chip, protein chips, and tissue & cell arrays find a number of uses in pharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostic centers, and other end users like point-of-care settings, forensic labs, blood banks, etc.
  • North America was the largest revenue-generating region and accounted for over 45%of total revenue in 2015. This can be attributed to by the presence of government initiatives for personalized patient care coupled with the availability of a very large installed base of genetic and proteomic profiling platforms across the U.S. High market usage of next-gen sequencing techniques for molecular diagnosis and treatment used with microfluidic techniques also add to the large share. Furthermore, cancer analysis projects in a number of academic and clinical research institutes are also responsible for the region's large share.
  • Some key players operating in this industry include Abbott Laboratories; PerkinElmer, Inc.; GE Healthcare; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Merck Millipore; Agilent Technologies, Inc.; Sigma-Aldrich Corporation; Fluidigm Corporation; and Bio-Rad Laboratories, Inc.

Grand View Research, Inc. has segmented the global biochip market on the basis of type, end-use and region:

  • Biochip Outlook, by Type (Revenue, USD Million, 2013 -2024)
    • DNA chips, by application
      • Cancer diagnosis and treatment
      • Gene expression
      • Single Nucleotide Polymorphisms Genotyping
      • Genomics.
      • Drug discovery
      • Agricultural biotechnology
      • Others
    • Lab-on-a-chip, by application
      • Genomics
      • IVD & POC
      • Proteomics
      • Drug discovery
      • Others
    • Protein chips, by application
      • Proteomics
      • Expression Profiling
      • Diagnostics
      • HTS
      • Drug Discovery
      • Others
    • Tissue Arrays
    • Cell Arrays
  • Biochip Outlook, by End Use (Revenue, USD Million, 2013 -2024)
    • Biotechnology and Pharmaceutical Companies
    • Hospitals and Diagnostics Centers
    • Academic & Research Institutes
    • Others
  • Biochip Regional Outlook (Revenue, USD Million, 2013 -2024)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
    • MEA
      • South Africa

Browse related reports by Grand View Research:

  • Human Embryonic Stem Cell Market - http://www.grandviewresearch.com/industry-analysis/human-embryonic-stem-cell-market

  • Expression Vectors Market - http://www.grandviewresearch.com/industry-analysis/expression-vectors-market

  • DNA Diagnostics Market - http://www.grandviewresearch.com/industry-analysis/dna-diagnostics-market

  • Pre-packed Chromatography Columns Market - http://www.grandviewresearch.com/industry-analysis/pre-packed-chromatography-columns-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. Thecompany provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Read Our Blogs - legalworkshop.org, grandviewresearch.com/blogs/healthcare

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com

© 2016 PR Newswire
Renditeturbo 2026 - 5 Aktien mit Potenzial
2025 neigt sich dem Ende zu, ohne klassische Jahresendrallye, aber mit einem DAX, der viele Kritiker Lügen gestraft hat. Über 21 Prozent Kursplus seit Jahresbeginn, stärker als der US-Markt. Wer hätte das noch vor Monaten erwartet?

Genau solche Entwicklungen machen den Reiz der Börse aus. Denn auch 2026 dürfte wieder alles anders kommen als gedacht. Während viele Analysten weiter steigende Kurse erwarten, rückt eine zentrale Frage in den Fokus: Wo entstehen im kommenden Jahr echte Überraschungen, und wie kann man davon profitieren?

Unser aktueller Spezialreport beleuchtet fünf Entwicklungen, mit denen kaum jemand rechnet, die aber enormes Renditepotenzial bergen. Vom Comeback der Ölwerte über unterschätzte Plattform-Aktien bis hin zur möglichen Wachablösung im KI-Sektor: Wer 2026 überdurchschnittlich abschneiden will, muss antizyklisch denken und frühzeitig Position beziehen.

Im kostenlosen Report stellen wir 5 Aktien vor, die 2026 im Zentrum solcher Wendepunkte stehen könnten. Solide bewertet, gut positioniert und mit überraschend starkem Momentum.

Jetzt kostenlos herunterladen! Bevor andere erkennen, wo die Chancen wirklich liegen!

Dieses exklusive PDF ist nur für kurze Zeit verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.